Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7976 - 8000 of 8170 in total
COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR...
Investigational
Matched Description: … [L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 …
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells . Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound...
Investigational
Matched Description: … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in …
Experimental
A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Investigational
Nutraceutical
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Description: … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who …
Compound with anti-depressive properties used as a mental performance enhancer.
Experimental
OXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). In addition, however, preclinical data demonstrates...
Investigational
Matched Description: … Preclinical studies have demonstrated that OXI-4503 has (i) single-agent activity against a range of
Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in the periodic table. It is a low-abundant metalloid that is a poor electrical conductor at room temperature. Natural boron exists in 2 stable isotopes however pure boron is hard...
Experimental
Matched Description: … agents, insecticides, semiconductors, magnets, wood preservatives, and an additive in glass fibers of
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers....
Investigational
Matched Description: … for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of
Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Investigational
CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Investigational
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Investigational
Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Investigational
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
TRC093 is a recombinant humanized IgG1k monoclonal antibody.
Investigational
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Investigational
Investigational
Displaying drugs 7976 - 8000 of 8170 in total